Welcome to our dedicated page for Dexcom news (Ticker: DXCM), a resource for investors and traders seeking the latest updates and insights on Dexcom stock.
DexCom, Inc. (DXCM) is widely described in its own communications as a global leader in glucose biosensing and real-time continuous glucose monitoring (CGM) for people with diabetes. The Dexcom news stream features regular updates on product launches, clinical evidence, coverage decisions, financial performance, and leadership developments, all centered on its CGM and biosensing technology.
Investors and healthcare observers following DXCM news will find detailed announcements on new products such as the Dexcom G7 15 Day CGM System, which is designed to provide real-time glucose readings over extended wear, and Dexcom Smart Basal, a CGM-integrated basal insulin dosing optimizer for adults with Type 2 diabetes using long-acting insulin. News items also cover enhancements to the Stelo app for metabolic health, AI-enabled features like meal logging, and integrations with connected devices and insulin delivery systems.
Dexcom’s news releases highlight clinical and real-world data presented at major conferences, including the European Association for the Study of Diabetes (EASD), where the company shares findings on outcomes such as pregnancy complications, diabetic ketoacidosis management, and cost-effectiveness of CGM compared to fingersticks. Coverage and reimbursement milestones, such as expanded access under the Régie de l’assurance maladie du Québec (RAMQ) and other public programs, are also frequent topics.
Financial results and guidance updates, leadership transitions, and board appointments are reported through earnings releases and Form 8-K related press announcements. For anyone tracking how CGM technology, biosensing, and digital health tools are evolving in diabetes and metabolic health, the Dexcom news page offers an ongoing record of the company’s product, clinical, and corporate developments. Bookmark this page to follow the latest DXCM press releases and regulatory disclosures as they are issued.
Dexcom (NASDAQ: DXCM) announces that the Dexcom G6 Continuous Glucose Monitoring (CGM) System is now eligible for provincial coverage in Manitoba for individuals with type 1 diabetes aged 25 and under. This move expands access to CGM technology, joining other provinces like British Columbia and Quebec that already provide coverage. The Dexcom G6 system allows users to monitor glucose levels continuously, reducing reliance on fingerstick tests. The initiative aims to improve diabetes management and health outcomes for young individuals with diabetes in Manitoba.
Dexcom (NASDAQ: DXCM) announces its G6 Continuous Glucose Monitoring (CGM) System is now covered by the Non-Insured Health Benefits (NIHB) Program for children and adolescents aged 2-19 requiring intensive insulin therapy. This coverage aims to improve access for First Nations and Inuit communities, potentially enhancing health outcomes for those living with diabetes. With proven benefits in glycemic control, the Dexcom G6 System provides real-time data and alerts, facilitating better diabetes management and support for families.
DexCom, Inc. (NASDAQ:DXCM) announced upcoming presentations at virtual investor conferences. Jereme Sylvain, CFO, will present at the Wells Fargo 2021 Virtual Healthcare Conference on September 10, 2021, at 2:00 PM EST. Quentin Blackford, COO, will present at the Morgan Stanley 19th Annual Healthcare Conference on September 13, 2021, at 2:00 PM EST. Webcasts will be available on the DexCom Investor Relations site for live viewing and future reference.
DexCom reported second quarter 2021 financial results with revenue growth of 32% year-over-year, totaling $595.1 million. U.S. revenue increased by 26%, while international revenue saw a remarkable 58% growth. GAAP operating income reached $101.0 million (17% of revenue), up 200 basis points from the previous year. DexCom announced an increase in its 2021 revenue guidance to approximately $2.35 - 2.40 billion, reflecting strong momentum in the CGM market. The company also received FDA clearance for its real-time API.
DexCom has received FDA clearance for its real-time Partner Web APIs, enabling third-party developers to integrate continuous glucose monitoring (CGM) data into digital health apps and devices. This advancement aims to enhance user experience by providing more flexibility in viewing glucose data. Companies like Garmin and Teladoc Health's Livongo are involved in the integration process. The APIs will help users consolidate therapy data and receive personalized diabetes management coaching.
DexCom, Inc. (NASDAQ:DXCM) will release its Q2 2021 financial results on July 29, 2021, after the market closes. Following the release, management will host a conference call at 4:30 p.m. ET to discuss the performance. Investors can access the call by dialing (800) 446-1671 for US/Canada or (847) 413-3362 for international calls, using the confirmation number 49591483. The call will also be webcast live, and the link will be available on the DexCom investor relations website.
DexCom, Inc. (NASDAQ: DXCM) recently highlighted key research at the 81st American Diabetes Association (ADA) virtual conference (June 25-29, 2021). The data emphasizes the critical role of continuous glucose monitoring (CGM) in diabetes management across various populations. Notably, presentations included analyses on CGM's effects on hypoglycemia control, glycemic control improvements, and healthcare cost reductions among Type 2 diabetes patients. Additionally, the conference showcased over a dozen studies linking CGM to enhanced health outcomes and quality of life.
DexCom (NASDAQ:DXCM) has launched The Global Movement for Time in Range, a campaign aimed at enhancing awareness and adoption of time in range metrics in diabetes management. Co-led by Nick Jonas, the initiative is backed by various diabetes organizations, aiming to inform patients about time in range's benefits and improve healthcare strategies. Survey data indicates that many insulin-treated diabetes patients lack awareness of this crucial metric, highlighting a significant opportunity for education and improved healthcare practices. The movement seeks to address these knowledge gaps.
Dexcom and Tandem Diabetes Care support Canadian athlete Sébastien Sasseville in his 14-day cycling challenge across Canada to raise awareness for diabetes technology access. The endeavor aims to highlight disparities in access to continuous glucose monitoring (CGM) systems across provinces. Recent announcements regarding public coverage of CGM systems in Quebec, Saskatchewan, and British Columbia reflect progress, yet inequalities persist. Sasseville uses the t:slim X2 insulin pump and Dexcom G6 CGM to manage his type 1 diabetes during the ride.
Dexcom (NASDAQ: DXCM) announces expanded provincial coverage for the Dexcom G6 CGM System through BC PharmaCare for individuals aged two years and older on intensive insulin therapy. This initiative aims to enhance diabetes management, providing broader access to life-changing technology. Notable endorsements from medical professionals highlight the positive impact of CGM on glycemic control and reduction in emergency room visits due to severe hypoglycemia. BC now joins other provinces in Canada offering public coverage for CGM systems.